-
Beta-blockers and noncardiac surgery; prenatal medication exposure and risk of autism; reasons for statin discontinuations; and FDA actions.
-
Clinically significant disparities exist in the quality of ovarian cancer care delivered and in overall survival along both racial and socioeconomic status. These effects appear to persist despite adherence to National Comprehensive Cancer Network guidelines; however, deviation in guideline adherence is common and further impacts survivorship and represents key opportunities for further investigation and study.
-
Current strategies to prevent chemotherapy-induced nausea and vomiting frequently include a 3-day course of aprepitant. In a multicenter trial from Japan, administration of a single dose of the aprepitant prodrug fosaprepitant, when used in combination with granisetron and dexamethasone, was shown to provide significant improvement when compared to placebo plus granisetron/dexamethasone. Thus, single-dose fosaprepitant may offer a more convenient and less complicated approach in the regimen to prevent nausea and vomiting.
-
-
In this study, the authors studied the prognostic value of plasma Epstein Barr virus (EBV) DNA levels at diagnosis and 6 months post-treatment in patients with advanced Hodgkin lymphoma treated on the North American Cooperative Intergroup Trial E2496.
-
In this Phase 2, single-arm, multicenter clinical trial conducted in the Netherlands, 50 patients with metastatic rectal cancer were treated with 5 days of 5 Gy RT followed by six cycles of intravenous bevacizumab (7.5 mg/kg) and oxaliplatin (130 mg/m2) on D1 and capecitabine (1000 mg/m2) orally on D1-D14.
-
-
Women undergoing pediatric cancer care are significantly more likely than their siblings to have clinical infertility (≥ 12 months of non-conception despite desired attempts) and total infertility (clinically infertile women who also reported ovarian failure defined as never initiating menstruation or no periods 5 years before baseline questionnaire).
-
-
Imatinib therapy was discontinued in 40 patients who had sustained undetectable BCR-ABL transcripts for 2 or more years, and close follow-up revealed approximately 50% remained with undetectable disease off treatment at 24 months.